- Home
- RARE vs OPCH Comparison
RARE vs OPCH Comparison
Compare RARE & OPCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- OPCH
- Stock Information
- Founded
- RARE 2010
- OPCH N/A
- Country
- RARE United States
- OPCH United States
- Employees
- RARE N/A
- OPCH N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- OPCH Medical/Nursing Services
- Sector
- RARE Health Care
- OPCH Health Care
- Exchange
- RARE Nasdaq
- OPCH Nasdaq
- Market Cap
- RARE 5.2B
- OPCH 5.0B
- IPO Year
- RARE 2014
- OPCH N/A
- Fundamental
- Price
- RARE $46.02
- OPCH $22.49
- Analyst Decision
- RARE Strong Buy
- OPCH Buy
- Analyst Count
- RARE 14
- OPCH 5
- Target Price
- RARE $86.79
- OPCH $31.20
- AVG Volume (30 Days)
- RARE 947.6K
- OPCH 2.9M
- Earning Date
- RARE 11-05-2024
- OPCH 10-30-2024
- Dividend Yield
- RARE N/A
- OPCH N/A
- EPS Growth
- RARE N/A
- OPCH N/A
- EPS
- RARE N/A
- OPCH 1.19
- Revenue
- RARE $522,745,000.00
- OPCH $4,776,174,000.00
- Revenue This Year
- RARE $27.29
- OPCH $16.68
- Revenue Next Year
- RARE $18.30
- OPCH $6.43
- P/E Ratio
- RARE N/A
- OPCH $18.58
- Revenue Growth
- RARE 27.44
- OPCH 13.58
- 52 Week Low
- RARE $37.02
- OPCH $21.39
- 52 Week High
- RARE $60.37
- OPCH $34.63
- Technical
- Relative Strength Index (RSI)
- RARE 34.61
- OPCH 34.91
- Support Level
- RARE $43.04
- OPCH $21.39
- Resistance Level
- RARE $53.04
- OPCH $23.28
- Average True Range (ATR)
- RARE 2.14
- OPCH 0.73
- MACD
- RARE -0.35
- OPCH 0.10
- Stochastic Oscillator
- RARE 28.57
- OPCH 45.08
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About OPCH Option Care Health Inc.
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders among others.